Supplementary Figure S1. Frequency distribution of novel non-synonymous de novo variants in ALS TRIO patients. The red line indicates the Poisson distribution (p = 0.5). The data fit well with the Poisson distribution suggesting that ALS risk is not caused by multiple de novo variants in a single individual. Supplementary Table S1 . Ages and clinical details of ALS TRIO patients, and ages of their parents. Blood sampling took place shortly after the onset of ALS in most patients. Weakness started in the limbs in most patients. The average ages of both fathers and mothers at the time of the ALS TRIO patients' births were similar to a large population of ALS parents in the Australian MND DNA Bank. Supplementary Table S2 . Transition transversion ratio (Ts/Tv) for coding, non-coding, and all bases per individual. Ts:Tv is the transition to transversion ratio. Across the whole genome, transitions (A>G and C>T) are expected to occur twice as frequently as transversions (A>C, A>T, G>C, G>T). In protein coding regions, the ratio observed is often slightly above 3. These values are comparable with previous whole exome sequencing studies. Supplementary Table S3 . Replacement (amino acid change) to silent (no amino acid change) ratio per individual. If a locus is evolving under neutral selection (i.e. no positive or negative selection) the ratio of replacement to silent sites should be constant. We tested for replacement to silent ratios greater than or less than one to identify sites that were under stronger or weaker selection. A simple calculation of the number of replacement divided by the number of silent sites gives an estimate of the rate of replacement to silent substitution. We found an enrichment of replacement sites (most likely caused by the annotation software) that chose the most damaging annotation when multiple annotations were available. Alt: alternative allele, Het: heterozygous, Hom: homozygous, Rep: replacement, Sil: silent. Supplementary Table S4 . All coding and non-coding rare de novo variants detected in ALS trio patients. The 54 de novo variants identified and validated are listed. The minor allele frequencies from the NHLBI ESP and 1KG projects and the dbSNP137 rsID are provided. Most variants are not previously reported and the previously reported variants that are in dbSNP137 have global minor allele frequencies less than 1%. Common variants that underwent Sanger validation passed manual review in IGV as de novo variants. Supplementary Table S5 . Coding variants in ALSoD genes in ALS trio patients. ALS coding susceptibility variants from ALSoD were assessed for frequency in this cohort. The global minor allele frequencies of each variant are shown in the NHLBI Exome Sequencing Project (ESP), 1000 Genomes Project (1KG), unaffected carriers in the present study, and affected carriers in the present study. Most variants are common alleles, and the global MAF of the alleles is similar to the frequencies in unaffected and affected carriers in this cohort. Supplementary Table S6 . Sequencing metrics. These values show the mapping and coverage information for the exome sequencing. The majority of reads aligned with a low rate of duplicate reads. We achieved almost 90% of bases mapping on target at 20X coverage. The transition transversion ratio (Ts:Tv) for coding bases is comparable with previous whole exome sequencing studies.
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Supplementary Methods

Exome sequencing
Genomic DNA from peripheral blood nucleated cells was extracted using QIAmp 96 DNA Blood Kits (Qiagen, Hilden, Germany). The integrity and yield of native genomic DNA was verified by a PicoGreen assay for quantitation and run on a 0.8% agarose gel for a qualitative QC. Illumina paired end small fragment libraries were constructed according to the manufacturer's recommendations with the following exceptions: (1) 500-1000 ng of native genomic DNA was fragmented using the Covaris E220 DNA Sonicator to a size range between 100-400 bp, (2) Illumina adapter-ligated library fragments were amplified in four 50 µL PCR reactions for eighteen cycles, (3) Solid Phase Reversible Immobilization (SPRI) bead clean-up was used for enzymatic purification throughout the library process, as well as final library size selection targeting 300-500 bp fragments.
Libraries were pooled pre-capture and hybridized to NimbleGen SeqCap EZ Human Exome Library kits (Roche NimbleGen, Madison, WI) according to manufacturer's protocol. Thirty samples were pooled to 4 libraries per pool and were processed on the v2.0 kits; 102 samples were pooled (5 libraries per pool) and processed on the v3.0 kits. The concentration of each captured library was accurately determined through KAPA qPCR according to the manufacturer's protocol to produce cluster counts appropriate for the Illumina HiSeq 2000 platform. The libraries were run on a HiSeq2000 V3 2x101 bp sequencing run according to manufacturer recommendations. Sequence data were aligned to the GRCh37-lite reference sequence using bwa version 0.5.9 1 . The targeted bases were defined by the v2.0 library kits, and 80% of targeted bases at 20X were required for the sample to pass quality control (QC). If Illumina OmniExpress genotype array data were available the sequencing data were also compared to the SNP calls. A 90% concordance rate was required for the sample to pass QC.
Variant calling and annotation pipelines
Variants were called using Samtools version r963 and VarScan 2.2.9 2 . Variants were filtered using read count information from the bam files which required a minimum base quality of 15, a maximum difference of mapping quality between variant and reference reads equal to 30, and a maximum difference of average supporting read length of 25, in addition to filters regarding homopolymer stretches, strandedness and minimum variant allele frequency. We restricted variant calling in all samples to a region of interest set that contains 34Mbp of consensus coding sequence, defined from the overlap between various versions of NimbleGen and Agilent exome capture reagents originally used in the TCGA project 3 . A 500 bp wingspan was added to each target region of interest on each side that adds an additional ~200 kbp of non-coding space. The dataset contained the unique union of the filtered calls from Samtools and VarScan, and genotype calls were combined from all individuals into a multisample vcf file. The site was removed if the false positive filter flagged 50% or more of the genotypes at a given position.
Familial relationships were verified using BEAGLE's fastIBD tool 4 to calculate the identity by descent between the child and expected parents. If a parent-child pair shared fewer than 40% of variants the entire trio was excluded.
A pedigree aware calling method, Polymutt 5 , that employs a likelihood-based framework, was utilised to call de novo variants in the trios. This method provides increased sensitivity and specificity when calling de novo point mutations by leveraging the parental genotype information when making calls.
The final variant set was annotated with dbSNP137 and Variant Effect Predictor (VEP) version 2.2 6 with the following parameters: --condel b --polyphen b --sift b --hgnc -canonical. For each gene, the canonical VEP annotation was used whenever possible. In the event of multiple overlapping genes that yielded different annotations, the most damaging annotation was used. Trio phasing was performed using BEAGLE v4 with default settings 7 .
Variants that intersected with sequence annotated in RepeatMasker and segmental duplications were excluded. All de novo variants were evaluated regardless of functional impact.
Two software programs were used to further annotate and aid in prioritizing variants, (A) Ingenuity Variant Analysis (IVA; www.ingenuity.com/variants) and (B) GEMINI v.0.6.3 8 .
(A) IVA employs a series of filters to assess functional consequences and impact of variants. Autosomal recessive and compound heterozygous variants were filtered with: (1) high confidence, read depth ≥ 20 and variants outside the top 1% of most exonically variable genes in healthy individuals, (2) rare variants, less than 1% frequency in Europeans from 1000 Genomes Project, NHLBI Exome Sequencing Project and Complete Genomics data, (3) predicted deleterious, predicted pathogenic or likely pathogenic, predicted gain of function, predicted loss of function (missense not tolerated by SIFT or PolyPhen2; frameshift, stop codon or essential splice site), (4) inheritance, homozygous, compound heterozygous, hemizygous, or haploinsufficient in cases but not controls, (5) affect motor neurons, diseases associated with motor neuron degradation, apoptosis, atrophy, demyelination, deficiency and damage. (B) Autosomal recessive and compound heterozygous variants were prioritized as candidates using GEMINI if they were: (1) coding, (2) rare, with a < 1% minor allele frequency in the 1000 Genomes and NHLBI Exome Sequencing projects, (3) deleterious or damaging, using SIFT, PolyPhen and Condel, and (4) highly conserved, using GERP. The unique union of the IVA and GEMINI variants was used as the list of candidate variants for manual review.
Candidate variants were manually reviewed using the Integrative Genome Viewer (IGV) 9 and eliminated from further analysis if reads supported mapping errors due to paralogous sequences, or in the case of de novo variants, if there was evidence for the variant in one of the parents.
Validation of variants
Candidate variants that passed manual review were independently validated with 3730 Sanger sequencing. Primers were designed using an in-house software program and tailed for 3730 sequencing. The amplification reaction consisted of a 5 ng DNA input, primer pairs, and the Amplitaq enzyme and amplified for 3 h in a thermocycler. After amplification, the product was cleaned up using a 1.5:1.0 Ampure bead-to-sample ratio. A Lonza flash gel was run to confirm product. Two sequencing reactions were completed using a 2 µL DNA input, Big Dye, and either the forward or reverse universal primer. Once complete, the sequencing reaction was precipitated using sodium acetate followed by a 70% ethanol wash. The DNA was dried down and then resuspended in EDTA and loaded on the 3730 sequencing platform.
